Conference Reports for NATAP

IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017 Back

Maviret /G-P in HIV+ Coinfected / ART DDIs       IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17)   IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17)   Additional slides